Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ESMO
Filter by Topic
ESMO 2010 Conference
ESMO 2011 Conference
ESMO 2012 Conference
ESMO 2013 Conference
ESMO 2014 - Gastrointestinal and Head & Neck Cancer
ESMO 2014 - Immuno-Oncology
ESMO 2014 - Prostate Cancer
ESMO 2014 Highlights
ESMO 2016
ESMO 2017 Highlights
ESMO 2018
ESMO 2019
Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase (PI3K) inhibitor in patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer. The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population.
Read Article
Rucaparib Maintenance Extends Survival
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
Madrid, Spain—Maintenance therapy with the poly ADP-ribose polymerase (PARP) inhibitor rucaparib (Rubraca) after response to platinum-containing therapy significantly improved progression-free survival (PFS) by 11.2 months in patients with recurrent ovarian cancer compared with placebo, according to overall results of the ARIEL3 trial. The study was presented at the 2017 European Society for Medical Oncology (ESMO) Congress.
Read Article
Potentially Practice-Changing Results: PD-L1 Inhibitor for Unresectable, Stage III Lung Cancer
By
Phoebe Starr
ESMO 2017 Highlights
,
ESMO
December 2017, Vol 8, No 5
Madrid, Spain—Durvalumab (Imfinzi), a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small-cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy. These results—presented at the 2017 European Society for Medical Oncology (ESMO) Congress—come from PACIFIC, the first phase 3 clinical trial of a PD-L1 inhibitor in patients with locally advanced NSCLC outside of the metastatic setting.
Read Article
Adjuvant Ipilimumab Therapy Shows Long-Term Survival Benefit in Patients with High-Risk Melanoma
By
Charles Bankhead
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—Adjuvant immunotherapy with ipilimumab (Yervoy) led to significant improvement in long-term overall survival (OS) among patients with high-risk melanoma, according to results from a 5.3-year follow-up in a randomized clinical trial reported at the 2016 European Society for Medical Oncology Congress and published simultaneously online.
Read Article
Immunotherapy Redefining the Treatment Strategy for Advanced Urothelial Cancer
By
Charles Bankhead
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—Two more PD-1 targeted drugs staked a claim to a role in treating advanced urothelial cancer, according to data from 2 studies that were reported at the 2016 European Society for Medical Oncology Congress.
Read Article
Ribociclib-Letrozole Combination Potentially Practice-Changing in Advanced Breast Cancer
By
Phoebe Starr
ESMO 2016
,
ESMO
November 2016, Vol 7, No 10
Copenhagen, Denmark—The addition of the selective cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib to letrozole (Femara) significantly improved progression-free survival (PFS) in patients with hormone receptor (HR)-positive advanced breast cancer. Compared with letrozole alone, the combination of ribociclib plus letrozole improved PFS by 44%.
Read Article
CLEOPATRA: Record-Breaking Survival in HER2 Metastatic Breast Cancer by Adding Pertuzumab
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Final results from the CLEOPATRA (Clinical Evaluation of Pertuzumab and Trastuzumab) trial show that dual HER2 blockade with the combination of pertuzumab and trastuzumab plus chemotherapy extended overall survival (OS) by almost 16 months compared with trastuzumab plus chemotherapy alone in patients with
HER2
-positive metastatic breast cancer.
Read Article
Mixed Results with Postprogression EGFR Inhibition in Advanced Non–Small-Cell Lung Cancer
By
Charles Bankhead
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Continuing an EGFR inhibitor after acquired resistance does not slow the progression of advanced non–small-cell lung cancer (NSCLC) in patients receiving chemotherapy, according to a report presented at the 2014 European Society for Medical Oncology (ESMO) Congress.
Read Article
New Data Show PFS, Survival Benefits with Bevacizumab in Breast Cancer
By
Charles Bankhead
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—The positive results from 2 studies raised speculation about a possible resurrection of the breast cancer indication for bevacizumab, as reported at the 2014 European Society for Medical Oncology Congress.
Read Article
PD-1–Blocking Nivolumab Shows Impressive Responses in Melanoma
By
Phoebe Starr
ESMO 2014 Highlights
,
ESMO
October 2014, Vol 5 , No 8
Madrid, Spain—Immunotherapy marches on, showing continued progress in treating advanced melanoma. At the 2014 European Society for Medical Oncology (ESMO) Congress, first reports from a phase 3 clinical trial showed that the monoclonal anti–PD-1 antibody nivolumab achieved superior responses and longer progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in the second- or third-line treatment of patients whose melanoma progressed with ipilimumab therapy.
Read Article
Page 3 of 8
1
2
3
4
5
6
7
8
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma